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Bacterialmeningitis and septicaemia is a global health problemoften caused byNeisseriameningitidis. The
complement system is the most important aspect of host defence against this pathogen, and the critical
interaction between the two is inﬂuenced by genetic polymorphisms on both the bacterial and the host
side; variations of the meningococcus may lead to increased survival in human sera, whereas humans
with complement deﬁciencies are more susceptible to meningococcal infections. Here we discuss the
mechanisms ofmeningococcal resistance against complement-mediated killing and the inﬂuence of both
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abacterial and host genetic
. Neisseria meningitidis and meningococcal disease
N. meningitidis is predominantly known for its leading role in
acterial meningitis and septicaemia worldwide but disease is a
are outcome compared with the high prevalence of carriage. The
eningococcus is an obligate bacterial commensal adapted to the
uman nasopharynx, where it resides asymptomatically in 10–40%
f the healthy population [1]. The carriage state is transient and
an last from days tomonths, depending on the bacterial strain [2].
poradically, some N. meningitidis strains can cross the epithelial
arrier and enter the bloodstream. Bacteria that have the abil-
ty to survive the bactericidal activities in the bloodstream may
ause severe sepsis, and some bacteria may cross the meninges to
ausemeningitis. The annual incidence of meningococcal infection
s highest in young children and varies from around 1 to 1000 cases
er 100,000 individuals [3,4]. The case-fatality rate is high despite
ppropriate treatment, ranging from 4 to 40%, with lower rates
4–6%) for individuals with meningitis alone, compared to up to
0% for thosewith septic shock [5]. Many survivors ofmeningococ-
al disease also suffer permanent tissue damage and neurological
roblems [6].
The underlying basis of the wide variation in outcome (from
symptomatic carriage to overwhelming sepsis) following acquisi-
ionof themeningococcus is still poorlyunderstoodbutwill include
enetic variation in the pathogen and in the host, as well as envi-
onmental factors. Humans are the sole reservoir ofN. meningitidis,
esulting in a host:pathogen co-evolutionary arms race that may
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ead toa fatal conditionsuchasmeningococcaldisease.Hostgenetic
actors, such as deﬁciencies in the complement system and genetic
olymorphisms ingenes involved in the immune system,havebeen
ssociatedwith increased susceptibility tomeningococcal infection
r increased severity of infection [5].
The single most important protective host factor against sys-
emic meningococcal infection is thought to be the presence of
erum bactericidal antibodies against the infecting strain [7]. Bac-
ericidal antibodies are acquired through carriage of meningococci
nd commensal species such as Neisseria lactamica, which express
ross-reacting epitopes on their surface [8–10]. The waning bac-
ericidal activity in infants, due to decreasing levels of passively
cquired maternal antibodies, is correlated with the highest rates
f meningococcal disease in young children [11]. Levels of serum
actericidal antibodies rise during childhood and adolescence, and
re thought to increase protection against meningococcal infection
12].
. Meningococcal population structure
Generation of genetic variants is crucial for the meningococcus
o adapt rapidly to the challenging environments of diverse hosts
nd to escape host immunity. Hence N. meningitidis has evolved
o become a highly diverse species due to horizontal exchange of
NA between strains and species [13], allelic diversity in some
enes (especially those under antigenic selection pressures) [14]
Open access under CC BY license.nd phase variation of gene expression [15]. Phase variation in N.
eningitidis is associated with high frequency reversible changes,
ithin simple DNA repeats composed of long homopolymeric
racts. These repeats can be located within promoters or cod-
ng regions, and thereby change gene expression by regulating
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ranscription or translation, respectively. Sequence analysis of N.
eningitidis strains has revealed over 60 putative phase-variable
enes [16] and most of these are associated with meningococcal
urface antigens including capsule [17], pili [18], outer membrane
roteins [19,20] and lipopolysaccharide (LPS) [21,22]. Mobile ele-
ents such as insertion sequences and Correia elements may also
hange the expression of surface antigens [23,24].
The extensive genetic diversity among meningococcal popula-
ions generates a few lineages with increased capacity to cause
nvasive disease, and such hyperinvasive lineages or clonal group-
ngs cause most meningococcal disease and are thought to arise,
pread and eventually disappear [25]. However, many variants
re only isolated rarely or in a single country due to bottlenecks
ssociated with competition and geographic spread, which limits
ransmission [26,27]. The general population structure ofN.menin-
itidis has been described as panmictic [28], as the bacterium is
ompetent forDNAuptake throughout all stagesof growth, andhor-
zontal genetic transferhashada signiﬁcant impact on its evolution.
or instance, alleles of penA, which encodes penicillin binding pro-
ein 2, have a mosaic structure in some strains, with regions even
cquired from other Neisseria spp. [29]. Furthermore, a single hor-
zontal transfer event can be sufﬁcient to convert the serogroup of
trains [30]. Despite frequent genetic exchange by transformation,
yping methods demonstrate that the population of N. meningitidis
s still highly structured, with pathogenic clones causing epidemic
such as serogroup A strains in sub-Saharan Africa) and endemic
isease (in developed countries) [13,31].
Traditionally, the meningococcus is classiﬁed by serological
yping methods based on structural differences of the polysac-
haride capsule (serogroup), the major outer membrane proteins
orB (serotype), and PorA (serosubtype), and LPS (immunotype).
athogenic meningococci are generally encapsulated and express
ne of six capsular polysaccharides, A, B, C, Y, W135, and recently
, [32], whereas carriage isolates are often non-serogroupable
unencapsulated) or express a different capsule (X, Z or 29E).
ost meningococcal carriage clones rarely cause disease despite
igh rates of transmission and acquisition [33,34]. The serologi-
al classiﬁcation system is limited due to high frequency of phase
nd antigenic variation of outer-membrane structures, which has
ed to the development of DNA-based approaches to characterise
eningococcal strains. The most important of these methods is
ultilocus sequence typing (MLST), where genetic variants atmul-
iple loci are identiﬁed on the basis of their nucleotide sequence
31]. The different variants are assigned an allele number, and the
ombination of allele numbers over multiple loci is designated as a
equence type (ST). Using seven housekeeping genes as a reference,
LST indicates the overall genetic variation in the meningococcal
enome. The concept of clonal complexes was introduced to repre-
ent a group of clones (STs) that are marginally different from one
nother but related enough to recognise a common ancestor [35].
o far, 38 clonal complexes have been described in N. meningitidis
http://pubmlst.org/neisseria) but only 11 of these are evidently
ssociated with disease [3].
. The role of complement and host genetic determinants
n meningococcal infection
Host genetic factors have a major impact on the development
f meningococcal infection. A study by Haralambous et al. suggests
hat one third of the total risk of contracting meningococcal infec-
ion is due to host genetics [36]. In particular, the complement
ystem plays a signiﬁcant role in defence against meningococcal
nfection, indicated by the increased susceptibility of patients with
omplement deﬁciencies [37]. There are three complement acti-
ation pathways: (i) the classical pathway, which is activated by
u
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p
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ntibody–antigen interactions; (ii) the alternative pathway, which
s activated bymicrobial surface structures through the interaction
f C3b with factor B and factor D; (iii) the lectin pathway, which is
ctivated when ﬁcolins or mannose-binding lectin (MBL) bind to
arbohydrates on microbial surfaces. All pathways result in cleav-
ge of C3 to C3b by a C3 convertase and subsequent downstream
ctivation of C5, leading to formation of the terminal C5–9 mem-
rane attack complex (MAC) on the bacterial surface. Pathogens
ith C3b bound to their surfaces are eliminated either by phago-
ytosis or cell lysis.
C3 is central to the complement system as it is the component
hat is at the convergence of all three activation pathways, and
leavage of C3 to C3b marks the start of the common ﬁnal bac-
ericidal mechanisms, lysis and opsonophagocytosis. Therefore, it
s not surprising that deﬁciency of C3 is associated with increased
usceptibility to meningococcal disease. Inherited C3 deﬁciency is
owever uncommon, but is associatedwith an increased incidence
f pyogenic infections, including those caused by N. meningitidis,
treptococcus pneumoniae, and Haemophilus inﬂuenzae. Most indi-
iduals with inherited C3 deﬁciency present early in life with
utoimmune complications [38,39]. Furthermore, acquired condi-
ions (e.g. systemic lupus erythematosus and glomerulonephritis
ue to C3 nephritic factor) that decrease the levels of circulating
3 increase the risk for invasive meningococcal disease by around
00-fold [40].
Deﬁciency of MBL is one of the most common inherited
mmunodeﬁciencies. Functional deﬁciency is observed in 5% of the
opulation but up to 35% of individuals carry variant alleles, which
ay cause decreased serum concentrations of MBL [41]. There are
hree allelic variants of MBL, whichwere associatedwith increased
usceptibility of children to meningococcal infection in cohorts
f patients recruited from hospitals and the community in Eng-
and [42]. These ﬁndings are of interest as MBL is central to the
ectin pathway of complement activation, and can act directly as
n opsonin on the meningococcus, as well as mediate generation
f a C3 convertase [43]. There is now further evidence in support
f the role of MBL in susceptibility tomeningococcal infection, par-
icularly in infancy [44].
The main regulator of the alternative pathway in the systemic
irculation is factor H. Interestingly, polymorphisms in the pro-
oter of the gene encoding factor H govern both serum levels
f this regulator and the relative risk of meningococcal infection
45]. Individuals with polymorphisms that lead to higher factor H
evels are more prone to meningococcal disease. Functional poly-
orphisms in sequences encoding factor H are relatively common
nd are associated with susceptibility to conditions such as Age-
elated Macular Degeneration and Haemolytic Uraemic Syndrome
46,47]. However, the inﬂuence of these and other polymorphisms
n the propensity for meningococcal infection has not been exam-
ned. Factor H is of particular interest since it has recently been
hown that binding of factor H to the meningococcus enhances
he bacterium’s ability to survive in the presence of human serum
48,49], this occurs via a lipoprotein on the surface of themeningo-
occus variously called R2086, GNA1870 and fHbp [49–51]. This
ipoprotein is expressed by all strains of N. meningitidis examined
o date and is a lead vaccine candidate. Mapping the precise site
f interaction between factor H and fHbp should provide insights
nto host speciﬁcity of the meningococcus and ways to construct
ariant proteins that do not bind factor H after being administered
s vaccines.Properdin, also known as factor P, is an important positive reg-
lator of the alternative pathway, which acts by stabilising its C3
onvertase, C3bBb; deﬁciencies can be due to decreased levels of
roperdin or normal levels of a dysfunctional protein. Three dif-
erent variants of properdin deﬁciency have been described and
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hey are all associatedwith increased susceptibility tomeningococ-
al infection. In addition, meningococcal disease in patients with
roperdin deﬁciency is associated with an increasedmortality rate
of between 33 and 75%) [52,53]. Complement factor D is another
mportantplayer in thealternativepathway. FactorD is a serinepro-
ease that cleaves and activates factor B, which can then associate
ith C3b to form the alternative pathway C3 convertase, C3bBb.
o far, two reports have described family members with severe
eningococcal infection and factor D deﬁciency [54,55].
Individuals with deﬁciencies of the late complement compo-
ents (C5–C9) fail to form theMAC and are thereforemore sensitive
omeningococcal infections, as hasbeendescribed in several family
tudies [56–58]. Complete genetic deﬁciency of any of the termi-
al components can lead to a 1000- to 10,000-fold increased risk
f meningococcal disease, often associated with recurrent infec-
ions caused by unusual serogroups [59]. Despite the high risk of
eningococcal disease, there is a 5- to 10-fold decrease in the
robability of death associatedwithmeningococcal infectionwhen
ompared to the general population, suggesting that the predispos-
ng condition to infection may also be protective [59].
. Molecular mechanisms of meningococcal serum
esistance
The major structures on the surface of N. meningitidis that con-
er resistance against the complement system are LPS and the
olysaccharide capsule. The importance of these molecules was
ighlighted in a screen of over 4000 insertional mutants, which
dentiﬁed 18 genes necessary for survival in the presence of human
erum [60]; all 18 genes are involved in the biogenesis of LPS or
apsule.
. Lipopolysaccharide
The LPS of N. meningitidis consists of a lipid A portion (also
eferred to as endotoxin), a relatively conserved inner core region,
inked to two carbohydrate chains, the  and  chains. There is
remarkable extent of structural diversity in LPS molecules, par-
icularly of the  and  chains, that can be expressed by the
eningococcus [61]. Panels of monoclonal antibodies can be used
o differentiate between 12 immunologically distinct LPS isoforms,
hich are the basis of the immunotype classiﬁcation of N. menin-
itidis.
In relation to escape from immune killing, some immunotypes
f LPS are structurally related to human blood group antigens. For
nstance, the  chain of L3,7,9 LPS contains a lacto-N-neotetraose
pitope which is identical to carbohydrate portions of glycosphin-
olipids present on human cells, providing an excellent example
f molecular mimicry by this human speciﬁc pathogen [62]. More-
ver, L3,7,9 LPS (as well as L2 and L5) can be further modiﬁed by
ialylation. In certain strains of N. meningitidis, sialic acid can be
ynthesized de novo and/or obtained from the external environ-
ent as in the gonococcus, and added into the terminal galactose
esidue of the  chain. There is unequivocal evidence that LPS
ialylation in N. gonorrhoeae enhances resistance against comple-
ent [63]. The effect of LPS sialylation in serum resistance in the
eningococcus is more ambiguous. Studies with clinical isolates
f serogroup C strains indicate that the degree of LPS sialylation
f strains correlates with their level serum resistance [64]. How-
ver, serogroup B mutants that are unable to sialylate their LPS do
ot display increased serum sensitivity compared to isogenic wild-
ype strains [65]. The difference in the contribution of sialylation
etween the gonococcus and themeningococcus is not fully under-
tood butmay be due to differences in the level of expression of the
ialyl transferase [24] or growth conditions [66]. Alternatively, any
t
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ffect of sialylation might be masked by an overriding inﬂuence of
he bacterial capsule in the meningococcus.
There is epidemiological and experimental evidence that the
mmunotype of an infecting strain inﬂuences its virulence. In the
etting of an outbreak of meningococcal disease, strains obtained
y nasopharyngeal swabbing predominantly expressed immuno-
ype L1,8,10 LPS,while virtually all disease related strains had L3,7,9
PS [67]. In support of this, two L1,8,10 expressing strains switched
o L3,7,9 following passage in a rodent model of meningococcal
epsis [68]. It is not clear what the basis is of this enhanced viru-
ence, although itmight bemediated by enhanced immune evasion
hrough mimicry or by LPS sialylation.
. The polysaccharide capsule
There is compelling evidence for the requirement of capsule
or virulence of N. meningitidis. First, almost all clinical isolates,
ecovered from the blood or the cerebrospinal ﬂuid, from infected
atients are encapsulated [69]. This is in sharp contrast to car-
iage strains, of which between 30 and 70% are unencapsulated
33,70]. Secondly, capsule negative mutants are highly sensitive to
illing in human serum [60,71]. Meningococci are divided into dif-
erent serogroups, based on antigenic differences in their capsular
olysaccharide. For unknown reasons, certain serogroups predom-
nate in different geographical locations. For example, serogroup A
trains cause the highest incidence of disease in the form of epi-
emics across sub-Saharan Africa known as the African Meningitis
elt [4]. Serogroup B and C strains, which have capsules composed
f homopolymeric sialic acid, cause endemic disease in developed
ountries. Serogroup B disease has a lower incidence although out-
reaks can be prolonged. Serogroups W135 and X have caused
isease in the African Meningitis Belt, with a W135 strain respon-
ible for a recent epidemic in Burkina Faso related to the Hajj
ilgrimage [72]. Cases of serogroup Y disease have been increasing
n incidence in the USA over the past decade [4].
It is not clear why certain serogroups cause most disease, given
hat several strains of other serogroups are regularly carried asymp-
omatically but rarely result in disseminated infection. It may be
hat thecapsulesofdisease causing strainshave inherentproperties
hat promote survival within the bloodstream, and it is interesting
hat the capsules of several ‘disease’ serogroups (i.e. B, C,W135, and
) contain sialic acid. Sialic acid is present on human endothelial
ells and erythrocytes where it inhibits the complement cascade
n the vascular compartment. It has been shown previously that
ialic acid containing capsules on the surface of the meningo-
occus and other pathogens [73–75] down-regulate the activity
f the alternative pathway, and thereby reduce ampliﬁcation of
3b production. The mechanism for this is unknown. Indeed, how
olysaccharide capsules of any chemical composition contribute to
mmune escape is still not clear even though they are expressed
y many extracellular pathogens. The biogenesis of the meningo-
occal capsule is encoded by a horizontally acquired 25kb region
nownas the capsule biosynthesis locus (cps),whichwas ﬁrst iden-
iﬁed as a region of the genome of serogroup B N. meningitidis that
as sufﬁcient to confer capsule expression when introduced into
scherichia coli [76]. The genetic organisation of the cps has been
tudied in detail in serogroup B strains [77]. The locus is organised
nto four distinct functional regions with one region containing an
peron (sia) responsible for the biosynthesis and polymerisation
f sialic acid, and another operon (ctr) involved in the export of
he capsule to the surface. These operons are separated by a 134bp
ntergenic region (IGR),whichharbors the control elements needed
or transcription of both operons [77]. The other two regions are
esponsible for phospholipid substitutions of the capsular polysac-
haride [78], and for LPS biogenesis [79]. Differences in sequence
accine
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ithin the cps between serogroup B and C strains are largely lim-
ted to the siaD gene,which governs the linkages between adjacent
ialic acid residues in the capsule; horizontal transfer of these
equences between strains by transformation can lead to cap-
ule switching [30]. Much less is known about the cps from other
erogroups.
Although capsule is an essential virulence factor, its expression
s regulated at different stages during infection and growth phase
80]. Loss of encapsulation has been shown to be associated with
ncreased bacterial adhesion to epithelial cells in vitro [17], and sev-
ral mechanisms may be responsible for loss of encapsulation. The
ost frequent change in serogroups B strains is phase variation in
iaD, which encodes the sialyl transferase. Other genes in sialic acid
iosynthesis or export of the capsule can be inactivated by an inser-
ion sequence, IS1301 [23]. Additionally, there are carriage isolates
hat entirely lack thegenes for capsuleproduction, so called capsule
ull locus (cnl) strains [81]. There have been a few case reports of
nl strains causing disease in immunocompromised patients [82],
ut rarely in apparently immunocompetent individuals [83]. Aside
rom on/off switching, the transcription of genes in the sia and ctr
perons varies during growth, with highest levels of expression
uring stationary phase [84]. Expression of capsule is thought to
e downregulated upon contact with host cells. This may be con-
rolled by a transcription factor, CrgA [85], although others have
ot seen an effect on capsule expression in a crgA mutant [80]. It
as recently suggested that the two-component regulatory system
isS/MisR, also known as PhoP/PhoQ [86], is involved in capsule
egulation [87]. However, the full details of how the expression of
his important virulence determinant is regulated still need to be
stablished.
Recently it has been shown in serogroup C N. meningitidis that
nsertion of IS1301 into the sia/ctr IGR leads to upregulation of
apsule expression and enhanced resistance against complement
ediated lysis [88]. IS1301 is an 844 bp element ﬂanked by 19
p inverted repeats, belonging to the IS5 family of transposons.
his insertion sequence is present in certain strains of N. menin-
itidis and N. gonorrhoeae in up to 17 copies in the genome [89].
nsertion and excision of IS1301 into siaA causes phase-variation of
apsule biosynthesis. IS1301 can also inactivate genes involved in
he expression of surface molecules such as capsule O-acetylation,
orA and NadA by inserting into ORFs [90–92]. In the IGR, insertion
eads to a dramatic upregulation in transcription through unknown
echanisms. In N. meningitidis, this polymorphism provides a
eneric mechanism for resistance against bactericidal antibodies
gainst non-capsular antigens such as PorA [88]. There is direct
vidence that increased amount of capsule reduces the activity of
he alternative pathway on the surface of bacteria. Additionally
t may shield surface antigens from circulating antibodies and/or
revent insertion of the MAC into the bacterial outer membrane,
hereby preventing lysis. Insertion of IS1301 in the IGR is not lim-
ted to serogroup C strains, and we have recently identiﬁed this
hange in serogroups B and Y strains. Indeed, this polymorphism
s present in over 30% of serogroup B disease isolates belonging
o clonal complex ST-269 in the UK (unpublished data). Addition-
lly, IS1301 has been found to be located at precisely the same
ite of the IGR in the opposite orientation and with variations in
ts sequence. However, the impact of these and other polymor-
hismsoncomplement-mediatedkillingneeds tobedeﬁned.Given
he importance of the capsule in immune evasion, there are likely
o be further polymorphisms in the cps that have similar protec-
ive effects against immune killing. The meningococcal genome is
epletewith repetitive sequences, and there is a large duplication in
he MC58 genome of around 31kb [93]. Therefore, it is conceivable
hat there are strains circulating that have ampliﬁcation of the cps,
s described previously in H. inﬂuenzae [94].
[
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. Concluding remarks
Deﬁciencies or polymorphisms in virtually all soluble com-
onents of the complement system are associated with altered
usceptibility to N. meningitidis, emphasising the critical impor-
ance of this aspect of the immune system in prevention of
eningococcal disease.On thebacterial side, thepresenceof repeat
nd mobile sequences in the genome, along with its ability to
cquire novel traits through transformation, mean that there is
ast genetic diversity among meningococcal strains that circulate
n humanpopulations. Detailed studies of the interactions between
he complement system and this highly adapted and versatile
athogen should provide insights that will allow us to understand
he host and pathogen traits that dictate whether acquisition of
. meningitidis leads to harmless colonisation or devastating dis-
ase. Furthermore, thismight also identify novel targets for vaccine
evelopment.
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